8-K: Curis Announces Promising Updated Data from TakeAim Leukemia Study, Highlighting Emavusertib's Potential in AML

Curis, Inc. released updated data from its TakeAim Leukemia study, showcasing encouraging results for emavusertib as a monotherapy in relapsed/refractory Acute Myelogenous Leukemia (AML) patients with specific genetic mutations.

Summary

• Curis, Inc. has announced updated data from the TakeAim Leukemia study, focusing on emavusertib as a monotherapy for relapsed/refractory AML.
• The study included 25 new patients with FLT3 and U2AF1/SF3B1 Splicing Factor mutations who had received fewer than three prior lines of therapy.
• In the FLT3 mutation cohort, 6 out of 11 response-evaluable patients achieved objective responses, including 3 complete remissions, 1 complete remission with partial hematologic recovery, and 2 morphologic leukemia-free states.
• Notably, 3 out of 3 patients who were naive to FLT3 inhibitor treatment achieved an objective response.
• In the Splicing Factor mutation cohort, 4 out of 18 response-evaluable patients achieved objective responses, including 1 complete remission, 2 complete remissions with partial hematologic recovery, and 1 morphologic leukemia-free state.
• All responders in both cohorts demonstrated complete normalization of blast counts in the bone marrow.
• The data cutoff for this update was February 26, 2024.
• The company also highlighted that several ongoing patients showed increased neutrophil counts, which is a positive clinical improvement for AML patients.

Sentiment

Score: 7

Explanation: The document presents positive clinical data for emavusertib, particularly in FLT3m-naive patients, but also highlights the company's need for additional funding, which introduces some uncertainty. The overall tone is optimistic but tempered by financial risks.

Positives

• Emavusertib demonstrated single-agent activity in both FLT3m and SFm AML patients.
• The drug showed rapid responses, with most responses occurring within the first cycle of treatment.
• The study showed a high objective response rate in FLT3i-naive patients.
• Increased neutrophil counts were observed in several ongoing patients, indicating a potential clinical benefit.
• The safety profile of emavusertib was acceptable in the study.

Negatives

• The study is still ongoing, and the data is preliminary.
• Not all patients responded to the treatment, with some not being response-evaluable.
• The company has a limited cash runway and will require additional capital to fund operations.

Risks

• Curis may experience delays or failures in its drug development programs.
• Emavusertib may not demonstrate sufficient safety and efficacy in later clinical trials.
• The company depends heavily on the success of emavusertib.
• Curis faces substantial competition in the pharmaceutical industry.
• The company needs substantial additional capital to fund its business and may be forced to delay or reduce its development programs if funding is not secured.
• There is a risk that collaboration agreements may not continue for their full term.
• Regulatory authorities may delay or restrict the commercialization of Erivedge, impacting royalty payments.
• Unstable market conditions and other external events could disrupt operations and impact the ability to raise capital.

Future Outlook

Curis anticipates presenting the updated data at the ASCO and EHA conferences and expects to achieve key milestones including POC combination data in R/R PCNSL and initial data for triplet combination in frontline AML by late-2024. The company believes its current cash is sufficient to achieve these milestones.

Management Comments

• Dr. Robert Martell, MD, PhD, Chief Scientific Officer of Curis, stated that the increase in neutrophils represents a meaningful clinical improvement for AML patients.
• James Dentzer, President and CEO of Curis, expressed encouragement by emavusertib's continued demonstration of single-agent activity, supporting its potential in both monotherapy and combination therapy in AML.

Industry Context

This announcement is significant as it provides further evidence of emavusertib's potential in treating AML, a challenging hematological malignancy. The focus on specific genetic mutations (FLT3m and SFm) aligns with the growing trend of personalized medicine in oncology. The results also position Curis as a potential competitor in the AML treatment landscape.

Comparison to Industry Standards

• In R/R FLT3m AML, emavusertib's CR/CRh rate of 50% (6 of 12 patients) compares favorably to historical benchmarks of around 21% for venetoclax/azacitidine, gilteritinib, and other FLT3 inhibitors.
• For R/R SFm AML, emavusertib's CR/CRh rate of 20% (4 of 20 patients) is notable, especially considering the poor prognosis associated with this mutation and the low response rates seen with other therapies such as azacitidine and venetoclax.
• The company is comparing the results to historical benchmarks, not head-to-head clinical trials, so direct comparisons should be made with caution.
• The results are particularly promising in FLT3i-naive patients, where emavusertib achieved a 100% objective response rate (3 of 3 patients).

Stakeholder Impact

• Shareholders may view the positive clinical data favorably, but the need for additional capital could cause concern.
• Employees may be encouraged by the progress of emavusertib but may also be concerned about the company's financial stability.
• Patients with AML may benefit from the development of emavusertib as a potential new treatment option.
• The company's financial situation may impact its ability to fulfill its obligations to suppliers and creditors.

Next Steps

• Curis plans to present the updated data at the ASCO and EHA conferences.
• The company will continue enrolling patients in the ongoing TakeAim Lymphoma, TakeAim Leukemia, and AML triplet studies.
• Curis aims to achieve proof-of-concept combination data in R/R PCNSL and initial data for triplet combination in frontline AML by late-2024.

Key Dates

Keywords

emavusertib, AML, leukemia, FLT3m, SFm, IRAK4, monotherapy, clinical trial, TakeAim Leukemia, oncology, hematology, cancer, biotechnology